A complete response letter (CRL) is the FDA's formal notice that a drug or biologic application cannot be approved in its present form, issued under 21 CFR 314.110 for new drug applications (NDAs) and abbreviated applications (ANDAs) and under 21 CFR 601.3 for biologics license applications (BLAs). The letter lists every deficiency FDA found and, where it can, the steps that would make the application approvable.
This guide uses the Atlas analysis of letters FDA has published through openFDA (data as of October 14, 2026) and the Atlas Form 483 database (release of August 15, 2026), so the counts below are dated and traceable.
- FDA issued 65 complete response letters in 2024, 48 in 2025 and 17 from January to June 2026, in the Atlas analysis of published letters (October 14, 2026).
- In 2024, 44 CRLs went to NDAs and 21 to BLAs.
- Clinical deficiencies appear in 56 of the 65 letters from 2024; facility inspection problems appear in 42.
- After a CRL, an NDA applicant must resubmit, withdraw or request a hearing under 21 CFR 314.110(b); a BLA applicant must resubmit or withdraw under 21 CFR 601.3(b).
- A Class 1 resubmission has a 2-month review goal and a Class 2 resubmission a 6-month goal; CDER's MAPP 6020.4 puts any resubmission that requires a reinspection in Class 2.
- FDA began publishing CRLs on July 10, 2025, and on September 4, 2025 said it would release new letters promptly after issuing them.
What is a complete response letter?
A complete response letter is the decision FDA sends at the end of a review cycle when it will not approve an application as submitted. Under 21 CFR 314.110(a), the letter must describe all the specific deficiencies the agency identified and reflects FDA's complete review of the data submitted. The BLA rule in 21 CFR 601.3 uses almost the same words.
Three details in the regulation matter to a quality team:
- FDA can issue a CRL without first inspecting the facility or reviewing labeling, if the data already fail to support approval (314.110(a)(3)). A CRL is no proof that your site passed.
- The letter goes to the applicant, not to the manufacturing site. A contract manufacturer whose inspection caused the CRL never receives it.
- Labeling comments often read "reserved" until the rest of the application is adequate, so a labeling line in a CRL is often a placeholder rather than a finding.
What happens after a complete response letter?
After a complete response letter, the applicant has three options for an NDA or ANDA and two for a BLA. 21 CFR 314.110(b) lists them, and the applicant must take one:
- Resubmit. The applicant addresses every deficiency. FDA classifies an NDA or BLA resubmission as Class 1 (final or draft labeling, safety or stability updates, assay validation data, minor reanalyses), which starts a 2-month review cycle, or Class 2 (everything else), which starts a 6-month cycle. CDER's MAPP 6020.4 Rev. 3 names "a resubmission requiring a reinspection" as Class 2. A major ANDA resubmission also gets a 6-month cycle.
- Withdraw. Withdrawal is without prejudice, so the sponsor can file again later.
- Request an opportunity for a hearing. This option exists for NDAs and ANDAs under 314.110(b)(3). Within 60 days, or a period both sides agree, FDA either approves the application or refuses it and gives notice of a hearing under 21 CFR 314.200. The BLA rule in 601.3 does not list it.
If the applicant does nothing for 1 year, FDA may treat the silence as a request to withdraw, unless the applicant asked for an extension. FDA grants any reasonable extension request.
The resubmission class is where a facility finding costs the most time. A CRL that rests only on labeling can close in 2 months. A CRL that needs FDA to inspect the facility again sits in the 6-month class, and the clock starts only when the resubmission arrives, after the site has fixed what the investigator found.
Complete response letter vs refuse to file vs approval: what is the difference?
A complete response letter comes after FDA has reviewed the whole application; a refuse-to-file letter comes before review starts, because the application is too incomplete to review. Approval is the other possible outcome at the end of the same review cycle.
| Refuse to file | Complete response letter | Approval | |
|---|---|---|---|
| When | Within 60 days of receipt | At the action date | At the action date |
| Regulation | 21 CFR 314.101 (NDA) | 21 CFR 314.110 (NDA, ANDA); 601.3 (BLA) | 21 CFR 314.105 (NDA); 601.4 (BLA) |
| What it means | Not complete enough for a substantive review | Reviewed, not approvable as submitted | Product may be marketed |
| Facility inspection | Not yet performed | Often performed; PAI findings can be the reason | Facility found acceptable |
| Applicant's next step | Correct and refile, or ask for an informal conference and file over protest | Resubmit, withdraw or request a hearing | Launch and meet post-marketing commitments |
The practical difference for manufacturing: a refuse-to-file decision never reaches your facility, while a CRL often follows a pre-approval inspection (PAI) of it. Our guide to FDA inspection types explains how application-based inspections differ from routine surveillance.
How many complete response letters does the FDA issue each year?
FDA issued 65 complete response letters in 2024, 48 in 2025 and 17 from January to June 2026, in the Atlas complete response letter analysis of letters published through openFDA (data as of October 14, 2026). 2024 is the highest year in that record.
| Year | NDA | BLA | Total CRLs |
|---|---|---|---|
| 2024 | 44 | 21 | 65 |
| 2025 | 28 | 20 | 48 |
| 2026, January to June | 10 | 7 | 17 |
Two cautions apply when you read these counts. They cover letters FDA has published, which is not every letter it ever issued, and FDA keeps adding to the set. And BLAs took a larger share in 2025 (20 of 48) than in 2024 (21 of 65), so a biologics sponsor should not read the lower 2025 total as lower risk.
Why does the FDA issue complete response letters?
Clinical deficiencies are the most common reason: they appear in 56 of the 65 complete response letters FDA issued in 2024, in the Atlas analysis (October 14, 2026). Facility inspection problems come second, in 42 of the 65. Clinical pharmacology appears in 11 and device-related issues in 5. Most letters cite more than one category.
The clinical number is the larger one, but the facility number is the one your quality unit controls. A sponsor cannot rerun a phase 3 trial in six months. It can close a Form 483 at its fill-finish site in that time, if it starts before the action date.
When FDA refuses on facility grounds, reviewers reuse the same sentences. In the September 2026 Atlas classification of published letters, four facility sentences recur: both the PAI and the CGMP surveillance inspection must be satisfactory (13 letters); the facility must answer the Form 483 to the FDA office named on it before the applicant responds to the CRL (22 letters); the CRL response must give the dates of those 483 responses (27 letters); and FDA may need to reinspect before it accepts them (10 letters).
Read together, the four sentences set an order of work. The facility answers its Form 483 first, the applicant cites those dates, and a reinspection may follow, which puts the resubmission in Class 2. If a site named in your filing has an open 483, you can check who inspected it and what they cited before FDA does.
AtlasSee what the FDA knows about your next investigator.
30 minutes with the founder. No pitch deck.
How does a Form 483 turn into a complete response letter?
A Form 483 turns into a complete response letter when FDA classifies the inspection of a facility named in the application as unacceptable, usually OAI, and the observations are still open at the action date. The letter goes to the applicant even when the site belongs to a contractor. Our explainer on what a Form 483 is covers the document itself.
Regeneron's 2025 letters show the chain. Its filings, summarized in our Regeneron Form 483 analysis, tie a July 30, 2025 CRL for odronextamab and an October 27, 2025 CRL for the EYLEA HD pre-filled syringe to a June 23 to July 14, 2025 inspection of Catalent Indiana, LLC in Bloomington, the contract filler. Regeneron said the only approvability issue in the October letter was the unresolved inspection findings. FDA sent Catalent Indiana warning letter 320-26-20 (MARCS-CMS 718189), dated November 20, 2025 and issued by CDER's Office of Manufacturing Quality, citing 21 CFR 211.192 first.
The Atlas record for that facility (release of August 15, 2026) shows 19 FDA inspections, 13 ending with a Form 483 and 11 with an EIR on file. The November 15, 2023 Form 483 cites six sections: 211.22(d), 211.67(b), 211.110(a), 211.113(b), 211.160(b) and 211.192. Six investigators are tied to it, including Andrew J Barrowcliff, whose Atlas profile lists 93 inspections across 79 sites, Alan L Truong, with 61 inspections, and Wendy G Tan, with 20. The 2025 warning letter cited 211.192 again. The most recent inspection on record, April 13 to 24, 2026, also ended with a Form 483.
The sections behind these letters are the ones FDA cites most often. Across 90 recent human-drug Form 483s in the Atlas database, 211.22 (quality unit) and 211.160 (laboratory controls) each appear on 32%, and 211.192 (production record review and investigations) on 31%. In 2025, FDA issued Form 483s with observation detail to 755 human-drug and 269 biologics inspections in the Atlas FDA Form 483 database (data to July 2026).
Are FDA complete response letters public?
FDA complete response letters have been public since July 10, 2025, when FDA published more than 200 letters (FDA press announcement, "FDA Embraces Radical Transparency by Publishing Complete Response Letters," July 10, 2025) for applications submitted between 2020 and 2024 that were later approved. On September 4, 2025, FDA released 89 more letters tied to pending or withdrawn applications and said it would release new CRLs promptly after issuing them.
Before that, a CRL became public only if the sponsor disclosed it, usually in a press release or SEC filing, and the sponsor chose the wording. The published letters carry FDA's own wording with trade secrets and confidential commercial information redacted. That is what makes counts like 42 of 65 possible.
How do you keep a facility from causing a complete response letter?
You keep a facility from causing a CRL by treating every site named in the application as part of the filing, and by closing its inspection history before the action date. Six checks, in order:
- List every facility in the application, including fillers, testing labs and API sources, with FEI numbers.
- Pull each site's inspection history and last classification from the FDA-inspected facilities directory. An OAI or open warning letter at a contract site is the Catalent pattern.
- Read each open Form 483 against the four recurring CRL sentences: is the response filed with the district office, dated, and complete?
- Keep one dated log of every 483 response for every site in the filing. The CRL response has to cite those dates.
- Plan the launch date on a Class 2 cycle if any site could need reinspection. Six months from resubmission is the realistic case.
- Line up a second filler or lab where one site carries a recent 483 history. Regeneron added fillers after its 2025 letters.
Submission planning tools help with steps 1, 4 and 5; our piece on smart automation for regulatory submissions covers where they fit.
Checks 2 through 4 sit with the quality unit. In 2024, 42 of the 65 complete response letters cited facility inspection problems.
AtlasFDA Inspection Intelligence Digest
We track every 483, EIR, and warning letter the moment it happens. Get the signals before they hit the FDA website.
Frequently asked questions
No. A complete response letter means the application cannot be approved in its present form. The applicant can fix the deficiencies and resubmit, and FDA reviews the resubmission on a 2-month or 6-month cycle. The first batch of letters FDA published in July 2025 covered applications that were later approved, so a CRL can be a delay rather than an end.
Written by
Bhavish Agarwal
Founder, Atlas
Bhavish Agarwal is the founder of Atlas and previously worked at Google and Microsoft. He has spent the past several years building regulatory data infrastructure for the pharmaceutical industry.
